These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

245 related items for PubMed ID: 17544313

  • 1. [Fetal toxicity of angiotensin-II-receptor inhibitors. Case report].
    Roger N, Popovic I, Madelenat P, Mahieu-Caputo D.
    Gynecol Obstet Fertil; 2007 Jun; 35(6):556-60. PubMed ID: 17544313
    [Abstract] [Full Text] [Related]

  • 2. Fetal toxic effects of angiotensin II receptor antagonists: case report and follow-up after birth.
    Bos-Thompson MA, Hillaire-Buys D, Muller F, Dechaud H, Mazurier E, Boulot P, Morin D.
    Ann Pharmacother; 2005 Jan; 39(1):157-61. PubMed ID: 15590878
    [Abstract] [Full Text] [Related]

  • 3. Severe neonatal renal failure after maternal use of angiotensin II type I receptor antagonists.
    Sinelli MT, Cattarelli D, Cortinovis S, Maroccolo D, Chirico G.
    Pediatr Med Chir; 2008 Jan; 30(6):306-8. PubMed ID: 19431954
    [Abstract] [Full Text] [Related]

  • 4. Aliskiren/valsartan (Valturna) for hypertension.
    Med Lett Drugs Ther; 2009 Nov 30; 51(1326):94-5. PubMed ID: 20224524
    [No Abstract] [Full Text] [Related]

  • 5. Valsartan in chronic heart failure.
    Ripley TL.
    Ann Pharmacother; 2005 Mar 30; 39(3):460-9. PubMed ID: 15687480
    [Abstract] [Full Text] [Related]

  • 6. Two amlodipine/ARB combinations for hypertension.
    Med Lett Drugs Ther; 2007 Dec 17; 49(1276):101-2. PubMed ID: 18084152
    [No Abstract] [Full Text] [Related]

  • 7. Gestational therapy with an angiotensin II receptor antagonist and transient renal failure in a premature infant.
    Bass JK, Faix RG.
    Am J Perinatol; 2006 Jul 17; 23(5):313-7. PubMed ID: 16799914
    [Abstract] [Full Text] [Related]

  • 8. Valsartan. Just a second-line antihypertensive drug.
    Can Fam Physician; 1999 Nov 17; 45():2626-8, 2630-3. PubMed ID: 10587770
    [Abstract] [Full Text] [Related]

  • 9. [Scientific evidence--applied in routine general practice. Successful decrease in pressure and risk].
    MMW Fortschr Med; 2006 May 04; 148(18):42-3. PubMed ID: 16736689
    [No Abstract] [Full Text] [Related]

  • 10. [Acute renal failure and hypertension].
    Bellido D, Sánchez de la Nieta MD, Vozmediano C, Oteros R, Zarca MA, Nieto J, Rivera F.
    Nefrologia; 2005 May 04; 25(5):563-7. PubMed ID: 16392308
    [Abstract] [Full Text] [Related]

  • 11. Angiotensin receptor blockers and myocardial infarction: the importance of dosage.
    Sarzani R, Dessì-Fulgheri P.
    J Hypertens; 2006 Aug 04; 24(8):1679-81; author reply 1681-2. PubMed ID: 16877973
    [No Abstract] [Full Text] [Related]

  • 12. New clinical investigations with selective angiotensin II receptor blocker therapy in diabetes and renal disease.
    Ruilope LM.
    J Renin Angiotensin Aldosterone Syst; 2000 Jun 04; 1(2 Suppl):S29-31. PubMed ID: 17199217
    [Abstract] [Full Text] [Related]

  • 13. Fetal toxic effects and angiotensin-II-receptor antagonists.
    Martinovic J, Benachi A, Laurent N, Daikha-Dahmane F, Gubler MC.
    Lancet; 2001 Jul 21; 358(9277):241-2. PubMed ID: 11480433
    [No Abstract] [Full Text] [Related]

  • 14. Proteinuria, chronic kidney disease, and the effect of an angiotensin receptor blocker in addition to an angiotensin-converting enzyme inhibitor in patients with moderate to severe heart failure.
    Anand IS, Bishu K, Rector TS, Ishani A, Kuskowski MA, Cohn JN.
    Circulation; 2009 Oct 20; 120(16):1577-84. PubMed ID: 19805651
    [Abstract] [Full Text] [Related]

  • 15. Valsartan-induced angioedema in a patient on angiotensin-converting enzyme inhibitor for years: case report and literature review.
    Kalra A, Cooley C, Palaniswamy C, Kalra A, Zanotti-Cavazzoni SL.
    Am J Ther; 2012 Nov 20; 19(6):e189-92. PubMed ID: 20838200
    [Abstract] [Full Text] [Related]

  • 16. Fetal toxicity of valsartan and possible reversible adverse side effects.
    Berkane N, Carlier P, Verstraete L, Mathieu E, Heim N, Uzan S.
    Birth Defects Res A Clin Mol Teratol; 2004 Aug 20; 70(8):547-9. PubMed ID: 15329835
    [Abstract] [Full Text] [Related]

  • 17. The safety of valsartan: results of a postmarketing surveillance study on 12881 patients in England.
    Biswas PN, Wilton LV, Shakir SW.
    J Hum Hypertens; 2002 Nov 20; 16(11):795-803. PubMed ID: 12444541
    [Abstract] [Full Text] [Related]

  • 18. Angiotensin II receptor antagonist treatment during pregnancy.
    Alwan S, Polifka JE, Friedman JM.
    Birth Defects Res A Clin Mol Teratol; 2005 Feb 20; 73(2):123-30. PubMed ID: 15669052
    [Abstract] [Full Text] [Related]

  • 19. Course and outcome of pregnancy after maternal exposure to angiotensin-II-receptor blockers--case report and review of the literature.
    Enzensberger C, Eskef K, Schwarze A, Faas D, Axt-Fliedner R.
    Ultraschall Med; 2012 Oct 20; 33(5):493-6. PubMed ID: 21630188
    [No Abstract] [Full Text] [Related]

  • 20. [New effective dosage of valsartan. High dosage--effective against high blood pressure].
    MMW Fortschr Med; 2007 Nov 15; 149(46):52-3. PubMed ID: 18069195
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.